Clinical and histological patterns and treatment of pyoderma gangrenosum

被引:10
|
作者
Chakiri, Radia [1 ]
Baybay, Hanane [1 ]
El Hatimi, Asmae [1 ]
Gallouj, Salim [1 ]
Harmouch, Taoufiq [2 ]
Mernissi, Fatima Zohra [1 ]
机构
[1] Univ Hosp Hassan II, Dept Dermatol, Fes, Morocco
[2] Univ Hosp Hassan II, Dept Anatomopathol, Fes, Morocco
来源
关键词
Pyoderma gangrenosum; neutrophilic dermatosis; systemic disease; MANAGEMENT; COMORBIDITIES;
D O I
10.11604/pamj.2020.36.59.12329
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Pyoderma gangrenosum (PG) is a rare inflammatory neutrophilic dermatosis for which accurate epidemiological data are limited and therapy remains a challenge. The primary study's aim was to examine all cases of PG observed in our department over a 6-year period in order to describe the relevant characteristics and outcome under therapy. Fourteen patients were included (5 women, 9 men). The average age of our patients was 40,15 years. The classical, ulcerative form was found in 10 cases (71.42%), the pustular form in 4 cases (27.57%) and PG was multifocal in 4 cases. The PG was located preferentially to the lower limbs. Histological examination was realized in all patients and objectified inflammatory infiltrate composed of polymorphonuclear neutrophils in all cases with vasculitis in 4 cases. Six patients (42.85%) had associated disease at diagnosis of PG, including inflammatory bowel disease in two cases (14.28%), a blood disease in 2 cases (14.28%), lymph node tuberculosis and inflammatory arthritis in 1 case (7%). The most frequent first-line treatments were oral corticosteroids (7 cases) and other treatments used were colchicine in 2 cases, topical corticosteroids in 3 cases with good clinical evolution. Our study confirms that PG is a rare disease, associated in almost half of cases with systemic disease already present at diagnosis; in our Moroccan background, it is most often inflammatory bowel disease, hematological or solid cancer and tuberculosis.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Treatment of pyoderma gangrenosum with intravenous immunoglobulin
    Cummins, D. L.
    Anhalt, G. J.
    Monahan, T.
    Meyerle, J. H.
    BRITISH JOURNAL OF DERMATOLOGY, 2007, 157 (06) : 1235 - 1239
  • [42] Recalcitrant pyoderma gangrenosum: Treatment with thalidomide
    Hecker, MS
    Lebwohl, MG
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1998, 38 (03) : 490 - 491
  • [43] TREATMENT OF PYODERMA-GANGRENOSUM WITH METHOTREXATE
    TEITEL, AD
    ARTHRITIS AND RHEUMATISM, 1993, 36 (09): : S163 - S163
  • [44] The treatment of pyoderma gangrenosum using etanercept
    Roy, DB
    Conte, ET
    Cohen, D
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (03) : S128 - S134
  • [45] Treatment of pyoderma gangrenosum with mycophenolate mofetil
    Kim, L. K. P.
    Hong, E.
    Cooper, A. J.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2011, 52 : 31 - 32
  • [46] TREATMENT OF PYODERMA-GANGRENOSUM WITH CYCLOSPORINE
    MATIS, WL
    ELLIS, CN
    GRIFFITHS, CEM
    LAZARUS, GS
    CLINICAL RESEARCH, 1991, 39 (02): : A507 - A507
  • [47] Pyoderma Gangrenosum: An Ulcer With Unorthodox Treatment
    Baruah, Tridip Dutta
    Ray, Rubik
    Manju, R.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (11)
  • [48] Infliximab as a treatment for recalcitrant pyoderma gangrenosum
    Singh, M
    Andrew, SM
    Lear, JT
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2004, 29 (02) : 196 - 197
  • [49] TREATMENT OF PYODERMA-GANGRENOSUM WITH CYCLOSPORINE
    MATIS, WL
    ELLIS, CN
    GRIFFITHS, CEM
    LAZARUS, GS
    ARCHIVES OF DERMATOLOGY, 1992, 128 (08) : 1060 - 1064
  • [50] Cavitary pyoderma gangrenosum and a novel treatment
    Tallon, Ben
    Rademaker, Marius
    Parkinson, Grant
    Whitley, Brian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (02) : AB43 - AB43